Abstract
Formal studies have not been performed to assess the cost-effectiveness of screening strategies for endocrine causes of hypertension. However, an understanding of the diagnostic accuracy of available screening tests and the clinical settings where disease identification will lead to improved health outcomes form the basis for a cost-effective strategy. Primary aldosteronism screening should be selective and restricted to settings where knowledge of the diagnosis has the greatest chance of improving health outcomes. Pheochromocytoma is rare; however, because it is a potentially fatal disease, screening strategies should err on the side of not missing the diagnosis, especially in high-risk clinical settings.
Original language | English (US) |
---|---|
Pages (from-to) | 279-294 |
Number of pages | 16 |
Journal | Endocrinology and Metabolism Clinics of North America |
Volume | 40 |
Issue number | 2 |
DOIs | |
State | Published - Jun 2011 |
Keywords
- Adrenal
- Diagnostic accuracy
- Screening
- Secondary hypertension
ASJC Scopus subject areas
- Endocrinology, Diabetes and Metabolism
- Endocrinology